Two top executives selling in the same window, with one exercising and immediately flipping options, is a cautionary signal. Monitor for upcoming clinical data readouts, earnings, or corporate events that may have prompted the selling.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 5 $15.75entry
- T+1 · 7mo ago +1.78%α +0.39% · $16.03
- T+5 · 6mo ago −54.79%α −56.78% · $7.12
- T+20 · 6mo ago −58.22%α −62.43% · $6.58
- T+60 · 4mo ago −56.89%α −60.37% · $6.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top executives at Entrada Therapeutics sold a combined $629K in open-market sales over a 7-day window, with President & COO Dowden also exercising and immediately selling derivative shares. The total sales represent ~0.11% of market cap, a modest but notable cluster involving both the COO and R&D President, suggesting insider caution ahead of potential catalysts or data readouts.
Key Financial Metrics
Key Facts
- President & COO Nathan Dowden sold 15,000 shares at $15.33 for $230K on May 4, 2026
- President of R&D Sethuraman Natarajan sold 25,907 shares at $15.39 for $399K on May 4, 2026
- Dowden also exercised 15,000 derivative shares at $1.74 ($26,100 cost) and immediately sold them
- Total open-market sales: $629K, representing ~0.11% of $563M market cap
- Cluster occurred in a 7-day window ending May 4, 2026
- No insider purchases were reported in this cluster
Financial Impact
Total insider sales of $629K, ~0.11% of market cap
Risk Factors
- Insider selling by both COO and R&D President may signal lack of near-term catalysts or concerns about upcoming data
- Derivative exercise and immediate sale suggests monetization rather than conviction holding
- Stock has appreciated significantly in recent months, increasing risk of mean reversion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TRDA-1777937131163 |
Track record
21 reports on TRDA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers